Neuren Pharmaceuticals Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos y los beneficios de Neuren Pharmaceuticals disminuyan a un ritmo anual de 2.6% y 9.9% respectivamente. Se espera que el BPA disminuya en un 14.1% al año. Se prevé que la rentabilidad financiera sea de 19% en 3 años.
Información clave
-9.9%
Tasa de crecimiento de los beneficios
-14.1%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 46.2% |
Tasa de crecimiento de los ingresos | -2.6% |
Rentabilidad financiera futura | 19.0% |
Cobertura de analistas | Good |
Última actualización | 18 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 209 | 109 | 103 | 88 | 5 |
12/31/2025 | 114 | 58 | 115 | 87 | 6 |
12/31/2024 | 194 | 113 | 36 | 69 | 5 |
6/30/2024 | 193 | 117 | 119 | 120 | N/A |
3/31/2024 | 213 | 137 | 152 | 152 | N/A |
12/31/2023 | 232 | 157 | 185 | 185 | N/A |
9/30/2023 | 155 | 106 | 120 | 120 | N/A |
6/30/2023 | 78 | 55 | 54 | 54 | N/A |
3/31/2023 | 47 | 28 | 29 | 29 | N/A |
12/31/2022 | 15 | 0 | 4 | 4 | N/A |
9/30/2022 | 9 | -3 | -3 | -3 | N/A |
6/30/2022 | 3 | -7 | -10 | -10 | N/A |
3/31/2022 | 3 | -7 | -10 | -10 | N/A |
12/31/2021 | 3 | -8 | -10 | -10 | N/A |
9/30/2021 | 2 | -10 | -10 | -10 | N/A |
6/30/2021 | 1 | -12 | -9 | -9 | N/A |
3/31/2021 | 1 | -11 | -9 | -9 | N/A |
12/31/2020 | 1 | -9 | -8 | -8 | N/A |
9/30/2020 | 1 | -8 | -9 | -9 | N/A |
6/30/2020 | 0 | -8 | -9 | -9 | N/A |
3/31/2020 | 0 | -9 | -10 | -10 | N/A |
12/31/2019 | 0 | -11 | -12 | -12 | N/A |
9/30/2019 | 7 | -6 | -5 | -5 | N/A |
6/30/2019 | 14 | -1 | 2 | 2 | N/A |
3/31/2019 | 14 | 1 | 4 | 4 | N/A |
12/31/2018 | 14 | 3 | 6 | 6 | N/A |
9/30/2018 | 7 | 3 | 0 | 0 | N/A |
6/30/2018 | 1 | 3 | -6 | -6 | N/A |
3/31/2018 | 1 | 3 | N/A | -6 | N/A |
12/31/2017 | 1 | 3 | N/A | -6 | N/A |
9/30/2017 | 2 | -2 | N/A | -7 | N/A |
6/30/2017 | 3 | -8 | N/A | -8 | N/A |
3/31/2017 | 3 | -10 | N/A | -10 | N/A |
12/31/2016 | 3 | -12 | N/A | -12 | N/A |
9/30/2016 | 2 | -14 | N/A | -14 | N/A |
6/30/2016 | 0 | -15 | N/A | -17 | N/A |
3/31/2016 | 1 | -14 | N/A | -15 | N/A |
12/31/2015 | 2 | -13 | N/A | -13 | N/A |
9/30/2015 | 2 | -11 | N/A | -11 | N/A |
6/30/2015 | 3 | -9 | N/A | -8 | N/A |
3/31/2015 | 3 | -9 | N/A | -7 | N/A |
12/31/2014 | 3 | -8 | N/A | -6 | N/A |
9/30/2014 | 3 | -10 | N/A | -7 | N/A |
6/30/2014 | 3 | -12 | N/A | -7 | N/A |
3/31/2014 | 4 | -11 | N/A | -7 | N/A |
12/31/2013 | 5 | -10 | N/A | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años (-9.9% al año).
Beneficios vs. Mercado: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años (-9.9% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de NEU disminuyan en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de NEU disminuyan en los próximos 3 años (-2.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de NEU disminuyan en los próximos 3 años (-2.6% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de NEU sea baja dentro de 3 años (19%).